Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds.

Thomas WilkeNils PickerSabrina MüllerAnna StürmlingerBarthold DeitersAxel DittmarJens AberleMaximilian Gabler

Published in: ClinicoEconomics and outcomes research : CEOR (2022)

Although the individual clinical patient profile and physician assessment are paramount in treatment decisions, substantial differences in the economic impact of different antidiabetic therapies should be considered.

Keyphrases

healthcare
emergency department
primary care
electronic health record
case report
cross sectional
big data
social media
data analysis
health information
deep learning